Recro Pharma rebrands itself as Societal CDMO in wake of Irisys purchase

Georgia-based CDMO Recro Pharma is rebranding itself as Societal CDMO in an effort to better communicate its services in the wake of a $50 million deal last summer for San Diego-based contract manufacturer Irisys.

Since the acquisition move in August, the company has been busy integrating facilities on both coasts, juggling a more diverse customer base and expanding its CDMO footprint.

Its rebranding is targeted at establishing the company as a drug manufacturing partner that meets its customers' objectives of delivering medicines that make a difference to society.

“We believe the name Societal CDMO, along with our new tagline of ‘Bringing Science to Society,’ captures not only where we find ourselves as a company today, but it reflects our inspiration for future growth as an organization,” David Enloe, chief executive officer of Societal CDMO, said in a statement.

Effective Tuesday, the company will begin trading on the Nasdaq under the symbol "SCTL." The name change will have no impact on the rights of stockholders. 

Prior to the acquisition, Recro was a specialist in oral solid dose drugs, and Irisys’ core businesses spanned formulation development to commercial manufacturing for a range of delivery formulations. With the integration of Irisys, Societal says it's better positioned to carry out pre-investigational development through commercial manufacturing and packaging work for customers in the U.S. and beyond.